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Abstract: Trimethoprim (TMP) is a dihydrofolate reductase (DHFR) inhibitor which 
prevents the conversion of dihydrofolic acid into tetrahydrofolic acid, resulting in the 
depletion of the latter and leading to bacterial death. Oral bioavailability of TMP is 
hindered by both its low solubility and low permeability. This study aims to prepare novel 
salts of TMP using anionic amino acids; aspartic and glutamic acid as counter ions in order 
to improve solubility and dissolution. TMP salts were prepared by lyophilisation and 
characterized using FT-IR spectroscopy, proton nuclear magnetic resonance (1HNMR), 
Differential Scanning Calorimetry (DSC) and Thermogravimetric analysis (TGA). Both the 
amino acids formed salts with TMP in a 1:1 molar ratio and showed a 280 fold 
improvement in solubility. Investigation of the microbiological activity of the prepared 
salts against TMP sensitive Escherichia coli showed that the new salts not only retained 
antibacterial activity but also exhibited higher zone of inhibition which was attributed to 
improved physicochemical characters such as higher solubility and dissolution. The results 
are an important finding that could potentially impact on faster onset of antibacterial 
activity and reduced therapeutic dose when administered to patients. Studies are underway 
investigating the effect of ion-pairing TMP with amino acids on the permeability profile of 
the drug. 
Keywords: trimethoprim; salt formation; fourier transform infrared; 1H nuclear magnetic 
resonance; thermogrametric analysis; Pseudomonas aeruginosa; minimum inhibitory 
concentration studies 
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1. Introduction 
Trimethoprim (Figure 1) [2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine], is a synthetic 
antibacterial agent belonging to a group of compounds known as diaminopyrimidines. It was first 
synthesized as a dihydrofolate reductase inhibitor (DHFR) and used mainly in combination with 
sulfonamides to treat pneumonia and urinary tract infections. TMP is administered through various 
routes including intramuscular, intravenous and oral and has high gastro-intestinal tolerability and low 
side effects. However, low aqueous solubility of TMP [1] reduces the bioavailability from oral 
formulations. In order to improve TMP dissolution profile, a study conducted by Li et al. utilized  
β-cyclodextrin to form a complex with TMP [2]. The study concluded that the high surface area of 
contact between TMP and the cyclodextrin along with reduction in drug crystalinity were responsible 
for improvement in TMP solubility [2]. Nevertheless, the solubility improvement achieved by this 
study was 2.2 fold. Besides, high doses of β-cyclodextrin are not recommended and can cause diarrhea 
and bloating as they are degraded and fermented by bacteria in the colon [3]. Therefore, investigation 
of alternative approaches to improve the solubility of TMP would have a high impact on oral 
administration of the drug. 
Interestingly, TMP has a basic nature (pKa 7.3) and a soluble derivative of the antibiotic can be 
obtained by reacting TMP with acids resulting in salt formation. Around 50% of the prepared salts of 
basic drugs are hydrochloride salts. Yet, hydrochloride salts salt out easily and in turn reduce the 
optimal solubility. Furthermore, hydrochloride salts usually cause high acidity in the formulations and 
high risk of corrosion [4], while the loss of volatile HCl could affect the stability of weak bases 
especially over the long-term [5]. Due to the limitations of hydrochloride salts, alternative counter ions 
that have been explored include citric acid, acetic acid, fumaric acid and maleic acid [5–7]. Another 
class of counter ions that can potentially address the solubility of basic drugs includes acidic amino 
acids. Fabrizio & Vetere utilized aspartic acid to prepare a water soluble salt of erythromycin. The 
obtained salt was used to prepare parenteral formulations of erythromycin and was found to be highly 
tolerable and less toxic [8]. Glutamic acid was used to prepare water soluble salts of chitosan and the 
glutamate salt was found to improve the apparent permeability of many drugs such as naproxen [9] and 
rokitamycin [10] when compared to chitosan alone.  
The present study aims to improve the solubility of TMP through salt formation with anionic amino 
acids, namely glutamic acid and aspartic acid and characterize the prepared salts using FT-IR 
spectroscopy, proton nuclear magnetic resonance (1HNMR), differential scanning calorimetry (DSC) 
and thermogravimetric analysis (TGA). The study also investigates the effect of different amino acid 
isomers on the salt characteristics and evaluates the inhibitory effect of the amino acids salts on 
intrinsically resistant bacteria. 
Figure 1. Trimethoprim chemical structure. 
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2. Materials and methods 
2.1. Materials 
Trimethoprim 98% TLC, L-glutamic acid, L-aspartic acid, D-aspartic acid (99%), D-glutamic acid 
(minimum 99% TLC) and Potassium bromide (99% FT-IR grade) were purchased from Sigma 
Aldrich, UK.  
D2O (99.9% min) was purchased from Coss scientific instrument Ltd. DMSO-D6 (98.8% min) was 
purchased from MERCK (Darmstadt, Germany). Tryptone Soya Broth (TSB) and Muller Hinton Broth 
(MHB) were purchased from Oxoid Ltd, Hampshire, England. 
2.2. Methods 
2.2.1. Analytical Technique 
The amount of Trimethoprim (TMP) dissolved in the solution samples was quantified using the 
HPLC (Dionex 1100 system) method reported by Gallego and Arroyo [11]. HPLC was operated at  
25 °C on RP-C18, (Phenomenex 110A, 150 × 4.6 mm, 5 µm) column using acetonitrile-NaH2PO4 
buffer (10 mM) (70:30, v/v) (pH 3) as mobile phase which was pumped at 1.0 mL/min flow rate using 
gradient pump (GP50). UV detector (UVD 170U) was used and the analysis was monitored at  
230 nm. The retention time was 1.74 ± 0.037 min and a rectilinear calibration curve was established at 
concentrations ranging between 10–500 µg/mL (R2 of 0.99). LOD and LOQ were calculated using 
standard deviation of response and slope and were found to be 0.109 and 0.364 respectively.  
2.2.2. Phase Solubility Diagram 
Phase solubility diagram was established by measuring the saturated solubility of TMP free base 
with various concentrations of acidic amino acid (L-aspartic acid and L-glutamic acid). Excess TMP 
was added into screw-capped tubes containing serial dilutions of the amino acid solutions and agitated 
at room temperature (Stuart SB 162 stirrer) for 24 h. After equilibrium, the supernatant was filtered 
through 0.45 µm filters and analysed by HPLC to determine TMP concentration. The pH of amino acid 
solutions was monitored using Xisherbrand Hydrus 500 pH meter. 
2.2.3. Salt Preparation 
Equimolar amounts of TMP and the free amino acids (L-aspartic acid and L-glutamic acid) were 
solubilized in water and the solutions were mixed and stirred until equilibration was achieved. The 
filtrate was transferred into vials and freeze dried for 48 h using a Modulyo freeze dryer at −40 °C 
shelf temperature and under vacuum. The samples were collected and kept in 40 °C oven for 4h using 
a Gallenkamp vacuum oven. 
Despite the low yield with freeze drying, it is a preferred technique unlike organic solvent methods 
adapted by Anderson & Conradi [12], as lyophilized products have a high degree of purity and are 
devoid of the formation of any solvates.  
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2.2.4. Thermogravimetric Analysis (TGA) 
A thermogravimetric analyzer (Pyris 1 TGA, Perkin Elmer) was used in this study to measure the 
moisture content and decomposition temperature of TMP and its prepared salts. 5–10 mg of samples 
were loaded on to an open pan and analyzed between temperature range 30–300 °C at 10 °C/min 
scanning rate and under nitrogen stream. Pyris Manager Software (version 5.00.02) was used to 
analyze the resultant thermograms. 
2.2.5. Differential Scanning Calorimetry 
Differential scanning calorimeter (Pyris Diamond DSC) was used to explore thermal events of TMP 
and its salts. Approximately 2–5 mg of the samples were weighted and transferred to an aluminum 
sample pan (50 µL capacity). Intra cooler 2P system was used to initially cool the samples to 50 °C 
and then sample heated to 300 °C at a rate of 10 °C/min. Nitrogen was used as a purge gas at a flow 
rate of 20 mL/min. Indium and Zinc were used to calibrate the heat flow and melting point onset 
(156.6 °C for Indium and 419.47 °C for Zinc). The obtained thermograms were analyzed using Pyris 
Manager Software (version 5.00.02). The experiment was performed in triplicate and an empty 
aluminum pan was used as a reference cell for all the measurements. 
2.2.6. FT-Infrared (IR) Spectroscopy 
FTIR absorbance spectra of TMP and its salts were obtained with Nicolet IR 200 spectrometer 
(Thermo electron corporation) using KBr discs. Crystalline KBr was dried at 65 °C over night before 
use. Samples were prepared by mixing TMP or its salts with dry KBr at 1:100 (w/w) ratio and pressed 
at 8 tons for 5 minutes (using Specac tablet presser) to form KBr discs. 64 scans were done over 
wavelength range of 4000–400 cm−1 for each sample. EZ OMNNIC 7.0 software was used to interpret 
the IR spectrum. 
2.2.7. 1HNMR 
Samples were studied with Bruker Avance DPX-250 NMR (at 250.1 MHz) and Bruker Topspin 
software was used to analyze the data. Approximately, 1–2 mg of the salts was dissolved in 1 mL of 
deuterated water (D2O) and placed in sample capillary vial. Sample vials were placed into the NMR 
machine and analyzed for the presence of hydrogen atoms (1H-NMR) 
2.2.8. pH Solubility Profile 
pH solubility studies were determined by using the Ledwidge & Carrigan method [13]. Saturated 
solution of the salts and acids were prepared by dissolving excess of the drug in deionized water. The 
solutions were agitated constantly using a stirrer (Stuart SB 162) at ambient temperature. pH was 
adjusted by adding NaOH or the appropriate acid (L-aspartic acid or L-glutamic acid). After 2 hour 
interval an aliquot was withdrawn and filtered through 0.45 µm filter, then analyzed using HPLC  
(see Section 2.2.1) 
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2.2.9. Solubility and Dissolution Studies 
Solubility studies were carried out using Hugchi and Connor’s method [14]. An excess amount of 
TMP or its salts was added to capped tubes with 5 mL of deionized water and stirred for 24 hours at 
room temperature until equilibrium was reached. Subsequently, the suspension was filtered through 
0.45 μm syringe filters and suitably diluted and the concentration was measured by HPLC. 
Hard gelatin capsules were filled with 200 mg of TMP or equivalent amounts of the prepared salts 
for dissolution studies. USP II paddle method (ERWEKA DT-600) was used to perform the in-vitro 
dissolution studies. The prepared capsules were placed into dissolution vessels containing 900 mL of 
distilled water (pH 7.2) and the dissolution media was maintained at 37 °C ± 0.5 °C and stirred at  
50 rpm. 5 mL of samples were collected at a predetermined time intervals (1, 5, 10, 20, 25, 30, 45 and 
60 min) then filtered through 0.45 μm Millipore filters. The dissolution media was replaced by 5 mL of 
fresh dissolution media in order to maintain a constant volume. After proper dilution samples were 
analyzed by HPLC as mentioned above. 
2.2.10. Microbiological Studies 
Two Gram-negative bacterial strains; Escherichia coli NCTC 10418 and Pseudomonas aeruginosa 
ATCC 9027 were used for this study. Freshly inoculated bacteria agar plate was prepared one day 
before the experiment by spreading colony suspension on Trypticase-soy agar plate and incubating for 
18 to 24 h.  
Zone of inhibition study was performed using Agar plates prepared using Trypticase-soy agar 
plates. Loopful of bacteria was spread gently on the surface of the agar plates. Six small holes were 
perforated on the agar plates and filled with 20 µL of 0.5 mM TMP or equivalent concentration of 
TMP salts. In order to evaluate any inhibitory effect of the amino acids on the bacterial growth, free 
amino acids were used as controls for this study. 
The bacterial minimum inhibitory concentration (MIC) of TMP and its prepared salts against the 
same two species of gram negative bacteria were performed using micro-dilution method and 
following the national committee for clinical laboratory standards (NCCLS) specifications. 
The bacteria inoculum was established by direct colony suspension method from 18 to 24 h 
Trypticase-soy agar plates, standardized and counted by Pharmacia spectrophotometer (Pharmacia 
LKB, Novaspec II). Around 5 × 106 CFU/mL was suspended in Tryptone Soya Broth and used in  
our study. 
50 µL of the bacterial inoculum was transferred to 100 µL of Muller Hinton Broth (MHB) at final 
concentration ranging between 0.5–0.00024 mM prepared by two fold dilution. 
Inoculated plates were incubated at 37 °C for 18–24 h. The lowest concentration of the antibacterial 
agent that inhibits the growth of bacteria was determined by visual turbidity when compared  
against control.  
2.2.11. Statistical Analysis 
Graph Pad Instat® software was used for the statistical analysis study. Data groups were compared 
using one way analysis of variance (ANOVA) and pair-wise multiple comparisons method (Tukey 
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test). Standard deviation (SD) was used to report the error in the figures and texts. Probability values of 
95% (P < 0.05) were used to determine the significant difference. 
3. Results and Discussion 
3.1. Phase Solubility Diagram 
Prior to preparing TMP salts, a solubility phase diagram was first constructed between TMP and 
two acidic amino acids; aspartic acid and glutamic acid as previously discussed by ElShaer et al. [15]. 
Figure 2 shows that increasing the anionic amino acid concentrations results in lowering of the solution 
pH and in turn improving the solubility of TMP. Aspartic acid has an acidic (–COOH) side chain with 
pKa of 1.88 which is 5 units lower than the pKa of TMP (pka 7.3). Therefore TMP could potentially 
act as a strong base in aspartic acid solution capable of deprotonating the –COOH acidic group. 
Interestingly, a linear relationship (R2 = 0.928) between TMP solubility and aspartic acid concentration 
was observed which suggests that complete ionization of TMP in aspartic acid solution was achieved 
suggesting the feasibility of salt formation. 
On the other hand, despite the slightly higher pka of the acidic side chain (-COOH) of glutamic acid 
(pKa = 2.19) a similar trend in solubility improvement was achieved possibly due to the ionization of 
TMP in solution. These results suggest that both glutamic and aspartic acid can be used in preparing 
novel salts of TMP. 
Figure 2. Phase solubility diagram of Trimethoprim (TMP) in the presence of different 
concentrations of glutamic acid and aspartic acid at different pH (n = 3). 
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3.2. Characterisation of Salt Form  
In order to evaluate the effect of isomer form on the salt characteristics, D and L isomers of 
glutamic and aspartic acid were used to prepare TMP salts. The prepared salts were further 
characterized by Fourier transform infra-red, differential scanning calorimetry, thermo-gravimetric 
analysis and 1H nuclear magnetic resonance. 
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3.2.1. Fourier Transform Infrared Spectroscopy (FT-IR) 
FT-IR was performed in order to assess any possible interaction between TMP and the acidic amino 
acids during salt formation and to investigate any possible changes that could occur due to the use of 
different isomeric forms of amino acids. 
The FT-IR spectra of TMP, TMP L-aspartate and TMP D-aspartate are shown in Figure 3. TMP has 
characteristic bands at 1634.3 and 1594.7 cm−1 which account for deformation of NH2 group and 
stretching of aromation ring respectively. Deformation of C9H2 group appeared at 1458.7 cm−1, while 
the vibration of C6=N of the aromatic primary appeared at 1263.71 cm−1. –OCH3 aromatic groups had 
characteristic bands at 1128.68 cm−1, as reported by Garnero et al. [16]. 
Assessment of TMP L-aspartate salt showed that TMP bands corresponding to NH2 and C-H 
aromatic stretching vibration were difficult to analyse due to overlapping with NH2 and CH aliphatic 
of the amino acid (Figure 3A). Interestingly, the C=N in the amine aromatic primary became very 
weak and a new band appeared at 1664.53 cm−1 corresponding to νC=O stretching which confirms that 
the cationic nitrogen has interacted with the carboxylic group of aspartic acid. In contrast, OCH3 
aromatic groups did not show any changes in the formed salt. 
Upon comparing the FT-IR spectra of the L-aspartate and D-aspartate salt, no difference was spotted 
between the two isomers (Figure 3A & B). 
Figure 3. FTIR spectra of (A) trimethoprim D-aspartate, (B) trimethoprim L-aspartate and 
(C) trimethoprim. 
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Figure 4 shows the FT-IR for TMP L-glutamate and TMP D-glutamate. Similar to the results 
obtained for aspartate salts, a new band appeared at 1656.87 cm-1 and 1654.74 cm-1 for TMP  
L-glutamate and TMP D-glutamate respectively. This band corresponds to the νC=O of the amino acid 
carboxylic group which when deprotonated potentially interacts electro-statically with the protonated 
A 
B
C 
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amino group of TMP prymidine ring. Both the L and D salts had similar FT-IR spectra and no 
significant difference was observed. 
Figure 4. FTIR spectra of (A) trimethoprim D-glutamate, (B) trimethoprim L-glutamate 
and (C) trimethoprim. 
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3.2.2. Differential Scanning Calorimetry and Thermogravimetric Analysis 
Figure 5 shows the TGA and DSC scans for TMP and L-glutamic acid. TMP had one single 
endothermic peak at 204.22 °C with an enthalpy of fusion of 166.7 J/g. TGA data revealed that TMP 
starts to degrade after around 30 °C of its melting. 
TMP L-glutamate salt was found to be in the crystalline form as no crystallization exotherm was 
observed in the DSC scans (Figure 6). At around 130 °C, TMP L-glutamate had an endothermic peak 
which could possibly correspond to moisture loss. Two endothermic peaks appeared at 197.22 °C  
(ΔH = 20.22 J/g) and 233.47 °C (ΔH = 150.02 J/g). This data suggests the presence of two 
enantiotrophs or monotrophs. A second scan was carried out after cooling and the results showed that 
the first thermal event was irreversible which suggests the presence of monotrophs rather than 
enantiotrophs. Interestingly, coupling the DSC scans with TGA showed a weight loss (4.03%) at  
196 °C which indicates that the thermal event is not a phase transition as polymorphic transitions are 
not associated with weight loss. In addition, 1HNMR data (discussed in details in Section 3.3.3) shows 
the absence of any impurities which provides further evidence that the weight loss is due to associated 
water molecules within the crystalline structure of the salt [17].” TGA was carried out to further 
validate DSC results as mass loss (which is routinely studied with TGA) indicates the presence of 
moisture [17]. 
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Figure 5. Thermogravimetric analysis (TGA) and Differential Scanning Calorimetry 
(DSC) scans for L-glutamic acid and TMP free base. 
 
Figure 6. DSC and TGA scans for TMP D-glutamate and TMP L-glutamate salts. 2–5 mg 
of the sample was heated to 300 °C at rate of 10 °C/min (n = 3). 
 
On the other hand, TMP D-glutamate salt is partially crystalline and the amorphous portion of the 
salt starts to crystallize at 140 °C. Moisture loss appeared as endothermic hump at around 80 °C 
corresponding to 1.62%. Similar to TMP L-glutamate, TMP D-glutamate showed hydrate loss at  
 
Pharmaceutics 2012, 4            
 
 
188
197.22 °C (ΔH = 18.16 J/g) appeared as small peak reflecting the small amount of the hydrate crystals 
formed during the freeze drying while the rest of the salt was in the amorphous state and crystallizes at 
140 °C as discussed before. After dehydration, the salt started to melt at 231.74 °C (Figure 6) similar 
results were suggested by [18]. 
The thermal events of TMP L-aspartate and TMP D-aspartate were studied using TGA and DSC 
(Figure 7). TMP L-aspartate showed an up drafted base line between 100–150 °C which corresponds to 
moisture loss and the salt converted from the amorphous form to the crystalline form at 160 °C 
followed by crystal melt at 184.22 °C. 
Figure 7. DSC and TGA scans for TMP D-aspartate and TMP L-aspartate. 2–5 mg of the 
sample was heated to 300 °C at rate of 10 °C/min (n=3). 
 
3.2.3. 1HNMR Studies 
The electronic and chemical environment of protons are affected during salt formation which could 
be reflected by the changes in δ. 1HNMR is considered a powerful tool in studying salt formation as it 
provides insight in to the ratio of molar interaction between the two moieties.  
Figure 8 shows the 1HNMR of TMP free base (solubilized in DMSO). At 7.53 ppm frequency one 
proton of TMP heterocyclic ring C4H appeared as singlet and the two protons on the aromatic ring 
C10H and C14H appeared at 6.56 ppm. The nine hydrogens of OCH3 groups appeared as two different 
peaks; (6H) appeared as a singlet at 3.73 ppm as they have the same surrounding environment, while 
the other (3H) appeared as a singlet at 3.63 ppm. The two hydrogens of aliphatic (C8H2) appeared as 
singlet at 3.54 ppm while two singlet bands appeared at 5.7 and 6.2 which correspond to N5H2 and 
N7H2 respectively. The total integrated H count for TMP was 18 (Figure 8). 
TMP L-aspartate salt (solubilized in D2O) showed new (3H) assignment at 2.6 corresponding to 
(C27H2) and a highly deshielded C25H group at 3.75 ppm, which represents the aliphatic chain of  
L-aspartic acid. As D2O was used as a solvent for TMP salts, NH2 groups were masked and the total 
integration of TMP aspartate salt was 17 instead of 21. These results confirm that one mole of  
L-aspartic acid interacts with 1 mole of TMP to form the salt (i.e, 1:1 ratio) as shown in Figure 9. 
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On the other hand, TMP L-glutamate had 5 new protons representing the aliphatic chain of the 
amino acid. (C28H2, C27H2) appeared at 1.96 and 2.2 ppm, while the third C25H group appeared at 
around 3.6 ppm due to the deshielding by NH2 group. The total integration also shows that 1 mole of 
L-glutamic acid interacts with 1 mole of TMP (Figure 10). 
Figure 8. 1HNMR spectra of trimethoprim free base solubilized in DMSO. 
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Figure 9. 1HNMR spectra of trimethoprim L-aspartate solubilized in D2O. 
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Figure 10. 1HNMR spectra of trimethoprim L-glutamate solubilized in D2O. 
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1HNMR studies of TMP D-aspartate and TMP D-glutamate salts did not reveal any difference in the 
spectra between the L and D isomers (Figure A&B Appendix 1). The high similarity of the salts 
formed despite using different isomers suggest that water used to solubilize the amino acids during the 
preparation step might provide free space for the rotation of the molecules and potentially catalyze 
racemisation as suggested by [19]. 
3.2.4. Aqueous Solubility and Dissolution Studies 
TMP is usually used in combination with sulfonamides in various formulations such as suspension, 
tablets and solution dosage forms. Therefore TMP solubility and dissolution are important 
determinants for its bioavailability.  
Solubility studies in our laboratory have found that the saturation solubility of TMP free base was 
0.217 mg/mL in water. Using acidic amino acids counter ions improved the solubility of the drug by 
around 280 fold when compared against the free drug. The solubility of the prepared salts was around 
55 mg/mL with no significant difference between the L and D isomers for both the counter ions 
(Figure 11). 
The dissolution profile of TMP and its different salts was also studied (Figure 12). Dissolution 
studies show a significant improvement of the salt form when compared to the free base. Around 70% 
of the TMP was released from aspartate and glutamate salt form after only 10 minutes of the 
dissolution experiment while only 10% release was seen from TMP free form (Figure 12). Such 
changes in the dissolution profile could be attributed to the ability of TMP salts to exert a  
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self-buffering action, which yield different pH values at the dissolving surface in the diffusion  
layer [20]. No significant difference was observed between the two salts, which suggest that both salts 
might have similar buffering capacity and hence similar pH at the diffusion layer. 
Figure 11. Solubility of trimethoprim and its prepared L & D aspartate and glutamate salts 
mean ± SD (n = 3). 
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Figure 12. Dissolution profile for TMP free base and its salts in deionized water. Data are 
mean ± SD (n = 3). 
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Table 1. pH measurements during solubility and dissolution studies. 
  Formulation 
pH 
measurement 
 TMP free base TMP Aspartate TMP glutamate 
Solubility study 
(Equilibrium) 
7.7 ± 0.05 5.075 ± 0.06 5.2 ± 0.11 
End of dissolution study 8.6 ± 0.07 5.37 ± 0.08 5.88 ± 0.05 
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3.2.5. pH-Solubility Profile 
TMP pka and intrinsic solubility are 7.3 and 0.19 mg/mL respectively. Figure13 shows the pH 
solubility profile of TMP when TMP glutamate salt and TMP free base were used as starting materials 
for determination of solubilities. The intrinsic solubility (Bs) was first determined by increasing the pH 
of TMP solution to 11.28 using NaOH and Bs was found to be 0.266 mg/mL. When TMP was used as 
a starting material the solubility was found to increase exponentially upon titrating with glutamic acid 
(Figure 13). TMP solubility increased from 0.37 mg/mL at pH 7.7 (point a) to 13.8 mg/mL at pH 4.23.  
Figure 13. pH solubility profile of TMP and TMP-glutamate salt at ambient conditions 
using free acid (circles) and TMP-glutamate salt (squares) as starting materials. Points b 
and a represent the saturation solubility of the salt and TMP free base respectively.  
[Bs] = 266.35µg/mL and pKa = 7.3. 
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On the other hand, when TMP glutamate salt was used as a starting point, the solubility started to 
decrease upon titrating with NaOH. TMP glutamate solubility was 53.6 mg/mL at pH 5 and decreased 
to 0.194 mg/mL at pH 11.9. A similar trend was observed upon titrating TMP with aspartic acid (data 
not shown). Generally, a good agreement was observed between the experimental values (squares and 
circles) and the theoretical predicted values (dotted line) see Table (2). Theoretical calculations were 
carried out using Kramer and Flynn [21] (Equation 1). 
][
]][[ 3
+
+
=
BH
OHB
Ka  
)1()( 3max
a
st K
OHBpHpHbaseS
+
==> )101( pHPkasB
−+=      (1) 
Where St is the total solubility at given pH, [Bs] is the intrinsic solubility of the free base and Ka is 
the acid dissociation constant. 
b
a
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Table 2. Theoretical calculations of pH solubility profile using (Equation 1).  
[Bs] = 266.35µg/mL and pKa =7.3. 
pH Solubility (µg/mL) 
11.28 266.35 
7.7 372.35 
6.3 2929.63 
6.1 4487.37 
5.7 10869.11 
4.9 67165.4 
3.2.6. Microbiology Studies 
After having significantly improved both the solubility as well as the dissolution characteristics 
using the salt forms of TMP, the next stage of the work was to evaluate microbiological properties to 
study if the therapeutic effect of the drug was still retained upon preparation of the different salts.  
Interestingly, zone of inhibition studies showed that use of amino acid salts not only retained the 
anti-bacterial activity against TMP sensitive species; Escherichia coli but also had a significant 
increase in the total area of inhibition (Table 3). To rule out the possible effects of amino acids alone 
on bacterial growth inhibition, control experiments with the amino acids were performed which 
resulted in no inhibition of bacterial growth on the plates. Therefore, the higher zone of inhibition can 
be attributed to the significant improvement in solubility which potentially results in higher 
permeability across the agar plates resulting in larger zone of inhibition. This could possibly translate 
into a faster therapeutic effect along with reduced therapeutic dose in a clinical setting. 
On the other hand, neither the drug nor the salts showed any activity against TMP resistance species 
Pseudomonas aeruginosa. This is probably due to the complex structure of Pseudomonas aeruginosa 
membrane as it is intrinsically resistant to TMP and prevents the entry of both the drug and amino  
acid salts. 
Table 3. Zone of inhibition studies of TMP and its prepared salts against Escherichia coli 
and Pseudomonas aeruginosa. 
 Escherichia coli Pseudomonas aeruginosa 
Area (cm2) % compare 
to the total 
plate area 
 
TMP 4.03 ± 0.2 18.7 **** 
TMP aspartate 4.6 ± 0.2 21.4 **** 
TMP glutamate 4.65 ± 0.2 21.6 **** 
Bacterial minimum inhibitory concentration was carried out as well in order to accurately determine 
the MIC of the TMP and its salts. Two species were used in this study; Escherichia coli and the 
intrinsically resistant organism, Pseudomonas aeruginosa. The MIC of TMP on E. coli was 0.00048 
mM and TMP aspartate and glutamate salt had similar MIC values which confirm our previous finding 
that salt preparation did not impair the pharmacological function of TMP (Table 4).  
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Table 4. MICs of TMP and its prepared salts against Escherichia coli and Pseudomonas 
aeruginosa. 
 Escherichia coli Pseudomonas aeruginosa 
TMP 0.00048 mM. >0.5 mM 
TMP aspartate 0.00048 mM >0.5 mM 
TMP glutamate 0.00048 mM >0.5 mM 
4. Conclusion  
TMP is a basic synthetic antibacterial agent which is poorly water soluble [1, 2]. In order to 
improve its solubility, the ability of TMP to form new salts with L and D isomers of acidic amino acids 
was investigated in this study. The study has demonstrated that TMP solubility increased significantly 
upon coupling with aspartic and glutamic acid and this increase was attributed to the novel salt 
formation which has self-buffering capacity yielding favorable pH for salt solubility during 
dissolution. Moreover, the antibacterial activity of these new salts was investigated and no change was 
seen in their MIC when compared against TMP free base. Using different isomers; L- and D- forms did 
not show any significant difference in the salt characteristics. Our future work will investigate the 
effect of amino acids salts on the absorption characteristics of TMP across intestinal membrane using 
Caco-2 cells. 
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Appendix  
Figure A. 1HNMR spectra of trimethoprim D-glutamate solubilized in D2O. 
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Figure B. 1HNMR spectra of trimethoprim D-aspartate solubilized in D2O. 
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